We have previously shown that Egr-1 is a transcription factor driving ROS-dependent Fyn expression in TKI-sensitive CML cells [37] however, little is known about differential Egr-1 expression in phases of CML, or its role in TKI-resistant disease. This evidence concerns the gene EGR1 and chronic myelogenous leukemia, BCR-ABL1 positive.